계명대학교 의학도서관 Repository

Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction

Metadata Downloads
Author(s)
Hyun Kuk KimMyung Ho JeongYoung Keun AhnJong Hyun KimShung Chull ChaeYoung Jo KimSeung Ho HurIn Whan SeongTaek Jong HongDong Hoon ChoiMyeong Chan ChoChong Jin KimKi Bae SeungWook Sung ChungYang Soo JangSeung Woon RhaJang Ho BaeJeong Gwan ChoSeung Jung Park
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
American Journal of Cardiology
Issued Date
2010
Volume
105
Issue
6
Abstract
Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and
in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several
studies. However, no data are available in direct comparison between the clinical outcomes of
the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction
(STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs
in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the
ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea
Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The
primary end points were major adverse cardiac events, a composite of all causes of death,
myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up.
During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use
of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common
in the SES group. The SES group had a significantly lower incidence of major adverse cardiac
events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p 0.02), target
lesion revascularization (HR 2.16, 95% CI 1.01 to 4.59, p 0.046), and target vessel revascularization
(HR 2.24, 95% CI 1.18 to 4.24, p 0.013). However, no significant differences were
found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p 0.129). In
conclusion, SESs provided superior angiographic outcomes, translating into better clinical
outcomes and negating any change in STEMI patient safety profiles compared to
ZESs. © 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:813–818)
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Hyun Kuk Kim et al. (2010). Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction. American Journal of Cardiology, 105(6), 813–818. doi: 10.1016/j.amjcard.2009.11.009
Type
Article
ISSN
0002-9149
Source
https://linkinghub.elsevier.com/retrieve/pii/S0002914909026794
DOI
10.1016/j.amjcard.2009.11.009
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34919
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Authorize & License
  • Authorize공개
  • EmbargoForever
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.